WO2004076613A3 - Humane nukleinsäuresequenzen aus harnblasenkarzinomen - Google Patents

Humane nukleinsäuresequenzen aus harnblasenkarzinomen Download PDF

Info

Publication number
WO2004076613A3
WO2004076613A3 PCT/DE2004/000364 DE2004000364W WO2004076613A3 WO 2004076613 A3 WO2004076613 A3 WO 2004076613A3 DE 2004000364 W DE2004000364 W DE 2004000364W WO 2004076613 A3 WO2004076613 A3 WO 2004076613A3
Authority
WO
WIPO (PCT)
Prior art keywords
bladder
carcinomas
nucleic acid
acid sequences
human nucleic
Prior art date
Application number
PCT/DE2004/000364
Other languages
English (en)
French (fr)
Other versions
WO2004076613A2 (de
Inventor
Alexander Herr
Bernd Hinzmann
Edgar Dahl
Eike Staub
Christian Pilarsky
Thomas Specht
Original Assignee
Alexander Herr
Bernd Hinzmann
Edgar Dahl
Eike Staub
Christian Pilarsky
Thomas Specht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexander Herr, Bernd Hinzmann, Edgar Dahl, Eike Staub, Christian Pilarsky, Thomas Specht filed Critical Alexander Herr
Publication of WO2004076613A2 publication Critical patent/WO2004076613A2/de
Publication of WO2004076613A3 publication Critical patent/WO2004076613A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft neue humane Nukleinsäuresequenzen aus Harnblasenkarzinomen, hierdurch codierte Proteine bzw. Peptide sowie deren Verwendungen im Zusammenhang mit der Diagnose und/oder Behandlung von Harnblasenkrebs.
PCT/DE2004/000364 2003-02-26 2004-02-24 Humane nukleinsäuresequenzen aus harnblasenkarzinomen WO2004076613A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2003109729 DE10309729A1 (de) 2003-02-26 2003-02-26 Humane Nukleinsäuresequenzen aus Harnblasenkarzinomen
DE10309729.5 2003-02-26

Publications (2)

Publication Number Publication Date
WO2004076613A2 WO2004076613A2 (de) 2004-09-10
WO2004076613A3 true WO2004076613A3 (de) 2005-01-06

Family

ID=32864187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2004/000364 WO2004076613A2 (de) 2003-02-26 2004-02-24 Humane nukleinsäuresequenzen aus harnblasenkarzinomen

Country Status (2)

Country Link
DE (1) DE10309729A1 (de)
WO (1) WO2004076613A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE510020T1 (de) * 2003-12-24 2011-06-15 G2 Inflammation Pty Ltd Transgenes nichtmenschliches säugetier mit einem polynukleotid, das für human-c5ar oder humanisiertes c5ar codiert
JP5051454B2 (ja) * 2005-08-04 2012-10-17 国立大学法人大阪大学 アポトーシス促進剤、細胞増殖阻害剤、癌の予防・治療剤、及びそのスクリーニング方法
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054447A2 (de) * 1998-04-21 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus blasentumorgewebe
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
WO2002086084A2 (en) * 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999054447A2 (de) * 1998-04-21 1999-10-28 Metagen Gesellschaft Für Genomforschung Mbh Menschliche nukleinsäuresequenzen aus blasentumorgewebe
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002086084A2 (en) * 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELIS J E ET AL: "LOSS OF ADIPOCYTE-TYPE FATTY ACID BINDING PROTEIN AND OTHER PROTEIN BIOMARKERS IS ASSOCIATED WITH PROGRESSION OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMAS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 20, 15 October 1996 (1996-10-15), pages 4782 - 4790, XP001189628, ISSN: 0008-5472 *
DATABASE EM-HUM [online] EMBL; 26 May 1999 (1999-05-26), RHODES S.: "Novel human gene mapping to chromosome 13", XP002292923, retrieved from EMBL Database accession no. AL049784 *
GROMOVA I ET AL: "PROTEIN ABUNDANCY AND MRNA LEVELS OF THE ADIPOCYTE-TYPE FATTY ACID BINDING PROTEIN CORRELATE IN NON-INVASIVE AND INVASIVE BLADDER TRANSITIONAL CELL CARCINOMAS", INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 13, no. 2, 1998, pages 379 - 383, XP008031678, ISSN: 1019-6439 *
O'BRIEN T ET AL: "THE ANGIOGENIC FACTOR MIDKINE IS EXPRESSED IN BLADDER CANCER, AND OVEREXPRESSION CORRELATES WITH A POOR OUTCOME IN PATIENTS WITH INVASIVE CANCERS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 11, 1 June 1996 (1996-06-01), pages 2515 - 2518, XP000857920, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
DE10309729A1 (de) 2004-09-16
WO2004076613A2 (de) 2004-09-10

Similar Documents

Publication Publication Date Title
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2005019264A3 (en) Human lxr alpha variants
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
IL169367A0 (en) Defensin proteins
WO2006016172A3 (en) Cell surface glycoprotein
WO2004096856A3 (en) Secreted protein family
WO2006043060A3 (en) Mam domain containing protein
WO2004076613A3 (de) Humane nukleinsäuresequenzen aus harnblasenkarzinomen
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IL169256A0 (en) Metalloprotease proteins
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2005046714A3 (en) Cytokine antagonist molecules
WO2004053117A3 (en) Serine protease
WO2001051518A3 (en) Nucleic acids encoding human semaphorin proteins and use thereof
WO2002062845A3 (en) Adhesion molecules
WO2004101618A3 (en) Progestin-yol002c-cgi-45 receptor-related proteins
WO2003085096A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004089282A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004050703A8 (en) Splice variant of the human pituitary growth hormone
WO2007049062A3 (en) Vwfa-domain containing proteins
WO2006051333A3 (en) Leucine-rich repeat (lrr) motif containing proteins
WO2004016654A8 (en) Il-8 like protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 69 1 EPC

122 Ep: pct application non-entry in european phase